



Expertise. Ingenuity. Affordability.

May 18, 2012 11:18pm EDT

US Medical Innovations, LLC Parent Company Signs Technology Transfer Agreement with George Washington University and Johns Hopkins University on Cold Plasma

US Patent Innovations, LLC (USPI) a private biomedical technology, research and development company, announced today that it has secured the rights to develop a technology that selectively eradicates cancer in vitro without damaging normal cells. USPI entered into a technology transfer agreement with George Washington University (Washington, D.C.) and Johns Hopkins University (Baltimore, MD). Under the agreement, the two universities assigned their patent rights encompassing cold plasma, a technology that selectively kills cancer cells. Research results have shown that the application of cold plasma therapy selectively eradicates cancer cells in vitro without damaging normal cells and significantly reduces tumor size in vivo.

US Patent Innovations, LLC (USPI) has formed a subsidiary, Plasma Medicine Life Sciences, LLC, for the purpose of developing Cold and Hybrid Plasma applications in cancer therapy. USPI's subsidiary, US Medical Innovations, LLC (USMI) presently markets and sells biomedical devices including the Canady Plasma® and Canady Vieira Hybrid Plasma™ lines of products using a new advanced electrosurgical energy "Hybrid Plasma Technology" which is a marked breakthrough in electrosurgery permitting surgery with virtually no blood loss and without the use of a traditional scalpel blade.

On October 6, 2011, scientists from George Washington University, Washington, DC, Applied Plasma Science LLC, Baltimore, MD, Children's National Medical Center, Washington, DC, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond VA and Johns Hopkins University, School of Medicine, Baltimore, MD, published a paper in the British Journal of Cancer (2011) 105, 1295-1301 on "Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy."

Commenting on the agreement, Jerome Canady, M.D., Chairman and CEO of USPI, said, "The development of Hybrid Plasma Technology and Cold Plasma Tumor Ablation will significantly shift the current paradigm of cancer therapy today".

©US Medical Innovations, LLC 2012

US Medical Innovations, LLC
Jerome Canady, M.D., CEO,
301-270-0147
Fax: 301-270-0849
info@usmedinnov.com
www.usmedinnov.com